Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Manifesto 2024
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
COVID-19
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Policy recommendations on uptake of biosimilar medicines in the retail market
Policy recommendations on uptake of biosimilar medicines in the retail market (November 2021)
Unlocking the potential of the biosimilar retail market (November 2021)
Retail policy algorithm: Policy recommendations to unlock the potential of the biosimilar retail market Retail policy algorithm – Paper version (November 2021)
Retail policy algorithm: Policy recommendations to unlock the potential of the biosimilar retail market Retail policy algorithm – Interactive version (November 2021)
Positioning Statements on Physician-led Switching for Biosimilar Medicines
Positioning statements on physician-led switching for biosimilar medicines (October 2021)
Biosimilar medicines group position on physician-led switching (July 2015)
Biosimilar medicines group position on biologic pharmacy substitution (September 2020)
Eco-Pharmaco-Stewardship (EPS) initiative – Care for People and Our Environment
Open
Open Public Consultation on the revision of EU rules on medicines for children and rare diseases
Open
Factsheet: Removing barriers to equitable access for timely competition
Open
Factsheet: Market and regulatory reforms to ensure availability and resilience of the supply chain
Open
Factsheet: Evaluating the impact of international trade on access to medicines
Open
Factsheet: Boosting affordable innovations
Open
The Issue of Abuses of Divisional Patent Application
Open
VAM Hurdles
Open
Medicines For Europe
Who we are
Manifesto 2024
Key topics
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Tweet
Tweet
Tweet
LinkedIn